Results 181 to 190 of about 10,287 (203)

FDA considerations regarding new hypolipidemic agents

Lipids, 1977
AbstractFood and Drug Administration policy being considered for new marketed hypolipidemic agents includes: long‐term safety to be demonstrated in postmarketing studies; evidence of clinical effectiveness to be demonstrated within a specified time period. Effectiveness is to be judged by one or more of the following: reduction in xanthomata, reduction
openaire   +3 more sources

ChemInform Abstract: The Hypolipidemic Agent Probucol. Mechanism of Action, Hypolipidemic Effects and Clinical Investigations

ChemInform, 1996
AbstractChemInform is a weekly Abstracting Service, delivering concise information at a glance that was extracted from about 100 leading journals. To access a ChemInform Abstract of an article which was published elsewhere, please select a “Full Text” option. The original article is trackable via the “References” option.
L. D. Smirnov, V. P. Lupanov, A. A. Lyakishev   +2 more
openaire   +2 more sources

Indole-Based Fibrates as Potential Hypolipidemic and Antiobesity Agents

Journal of Medicinal Chemistry, 2012
Hypolipidemic and antiobesity effects of the newly synthesized indole-based fibrates were evaluated in Triton WR-1339 and high fat diet (HFD)-induced hyperlipidemic rats. Preliminary screening of all the synthesized compounds was done by using an acute model (Triton model), in which compounds 3f and 3l showed significant antidyslipidemic activity ...
Koneni V. Sashidhara, Gitika Bhatia, Bhanu Shankar Singh, Manoj Kumar, A.K. Khanna, Ravi Sonkar   +5 more
openaire   +3 more sources

Synthesis and Biological Evaluation of Orally Active Hypolipidemic Agents

Journal of Medicinal Chemistry, 2011
A series of novel fenofibric acid ester prodrugs 1c-1h were synthesized and evaluated with the aim of obtaining potent hypolipidemic agents. Prodrugs 1c and 1d exhibited potent hypochlolesterolemic activity, lowering the mice plasma triglyceride level up to 47% in Swiss albino mice after oral administration of 50 mg/kg/day for 8 days.
Rajendra J. Sarangdhar, Jeyamurugan Mookkan, Pranesha Shetty, Babasaheb P. Bandgar, Gajendra Singh, Fruthous Khan   +5 more
openaire   +2 more sources

Investigation of 3,5-isoxazolidinediones as hypolipidemic agents in rodents.

Pharmaceutical research, 1995
A series of 2-benzoyl-4,4-dialkyl-3,5-isoxazolidinediones proved to have potent hypolipidemic activity, lowering both serum cholesterol and triglyceride levels at 10 or 20 mg/kg/day, IP and orally in rodents. 2-(3,4,5-Trimethoxybenzoyl)-4,4-diethyl-3,5-isoxazolidinedione+ ++ (4) afforded the best hypolipidemic activity lowering normolipidemic CF1 mouse
Dwayne L. Daniels, Hamby ElSourady, Iris H. Hall, Tyrone Woodard, R. Simlot, Manik L. Debnath, Oi T. Wong, Robert A. Izydore   +7 more
openaire   +3 more sources

ChemInform Abstract: STUDIES ON HYPOLIPIDEMIC AGENTS PART 2, SYNTHESES AND HYPOLIPIDEMIC ACTIVITIES OF PHENOXYACETYLINOSINE DERIVATIVES

Chemischer Informationsdienst, 1974
AbstractAus (I) erhält man das Ketal (II), das über (III) die Phenoxyacetylinosine (IV) ergibt.
K. Hiraoka, K. Nagao, M. Hirohashi, E. Sakakibara, F. Miyoshi   +4 more
openaire   +2 more sources

Micronized Fenofibrate: A New Fibric Acid Hypolipidemic Agent

Annals of Pharmacotherapy, 1999
OBJECTIVE: To review the efficacy and safety of fenofibrate in the management of hyperlipidemias. DATA SOURCES: A MEDLINE search (1974–October 1998), Current Contents search, additional references from article bibliographies, and the package insert from the manufacturer were used to identify data for evaluation.
openaire   +3 more sources

Metabolism of the hypolipidemic agent tiadenol in man and in the rat.

Arzneimittel-Forschung, 1986
The metabolism of the hypolipidemic agent 1,10-bis(hydroxyethylthio)decane (tiadenol, Eulip) has been studied in vivo in man and in the rat and in vitro in the rat. Following oral administration, in both species tiadenol was completely absorbed, extensively metabolized by the liver and more than 95% of the dose was eliminated in this form via kidneys ...
R. MAFFEI FACINO, M. CARINI, O. TOFANETTI   +2 more
openaire   +2 more sources

Nitric Oxide Releasing Morpholine Derivatives as Hypolipidemic and Antioxidant Agents

Journal of Medicinal Chemistry, 2002
The synthesis and evaluation of activity of some nitric acid esters of substituted morpholines are presented. All compounds inhibit lipid peroxidation and reduce cholesterol (20-63%) and triglyceride (37-85%) plasma levels. The more potent NO donors 14 and 17 specifically reduce low-density lipoprotein (LDL).
Eleni A. Rekka, Ioanna C. Siskou, Panos N. Kourounakis, Michael C. Chrysselis   +3 more
openaire   +3 more sources

Studies on antidiabetic agents. 11. Novel thiazolidinedione derivatives as potent hypoglycemic and hypolipidemic agents

Journal of Medicinal Chemistry, 1992
AbstractChemInform is a weekly Abstracting Service, delivering concise information at a glance that was extracted from about 100 leading journals. To access a ChemInform Abstract of an article which was published elsewhere, please select a “Full Text” option. The original article is trackable via the “References” option.
Kanji Meguro, Katsutoshi Mizuno, T. Fujita, Hitoshi Ikeda, Yu Momose, Takashi Sohda   +5 more
openaire   +4 more sources